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ResearchUpregulation of FOXM1 induces genomic 
instability in human epidermal keratinocytes
Muy-Teck Teh*1, Emilios Gemenetzidis1, Tracy Chaplin2, Bryan D Young2 and Michael P Philpott3
Abstract
Background: The human cell cycle transcription factor FOXM1 is known to play a key role in regulating timely mitotic 
progression and accurate chromosomal segregation during cell division. Deregulation of FOXM1 has been linked to a 
majority of human cancers. We previously showed that FOXM1 was upregulated in basal cell carcinoma and recently 
reported that upregulation of FOXM1 precedes malignancy in a number of solid human cancer types including oral, 
oesophagus, lung, breast, kidney, bladder and uterus. This indicates that upregulation of FOXM1 may be an early 
molecular signal required for aberrant cell cycle and cancer initiation.
Results: The present study investigated the putative early mechanism of UVB and FOXM1 in skin cancer initiation. We 
have demonstrated that UVB dose-dependently increased FOXM1 protein levels through protein stabilisation and 
accumulation rather than de novo mRNA expression in human epidermal keratinocytes. FOXM1 upregulation in 
primary human keratinocytes triggered pro-apoptotic/DNA-damage checkpoint response genes such as p21, p38 
MAPK, p53 and PARP, however, without causing significant cell cycle arrest or cell death. Using a high-resolution 
Affymetrix genome-wide single nucleotide polymorphism (SNP) mapping technique, we provided the evidence that 
FOXM1 upregulation in epidermal keratinocytes is sufficient to induce genomic instability, in the form of loss of 
heterozygosity (LOH) and copy number variations (CNV). FOXM1-induced genomic instability was significantly 
enhanced and accumulated with increasing cell passage and this instability was increased even further upon exposure 
to UVB resulting in whole chromosomal gain (7p21.3-7q36.3) and segmental LOH (6q25.1-6q25.3).
Conclusion: We hypothesise that prolonged and repeated UVB exposure selects for skin cells bearing stable FOXM1 
protein causes aberrant cell cycle checkpoint thereby allowing ectopic cell cycle entry and subsequent genomic 
instability. The aberrant upregulation of FOXM1 serves as a 'first hit' where cells acquire genomic instability which in 
turn predisposes cells to a 'second hit' whereby DNA-damage checkpoint response (eg. p53 or p16) is abolished to 
allow damaged cells to proliferate and accumulate genetic aberrations/mutations required for cancer initiation.
Background
The forkhead box (FOX) transcription factors have been
shown to regulate cell growth, proliferation, differentia-
tion, longevity and transformation and exhibit a diverse
range of functions during embryonic development and
adult tissue homeostasis [reviewed in [1]]. FOXM1-null
mouse embryos were neonatal lethal as a result of the
development of polyploid cardiomyocytes and hepato-
cytes, highlighting the role of FOXM1 in mitotic division
[2]. More recently a study using transgenic/knockout
mouse embryonic fibroblasts and human osteosarcoma
cells (U2OS) has shown that FOXM1, regulates expres-
sion of a large array of G2/M-specific genes, such as Plk1,
Cyclin B2, Nek2 and CENP-F, and plays an important role
in maintenance of chromosomal segregation and
genomic stability [3].
A key intrinsic mechanism that determines cell survival
and apoptosis is the ability to detect and respond to geno-
toxic insults such as chemical carcinogens, ultraviolet or
ionising irradiation. Failure to regulate DNA damage
response checkpoints and subsequent genomic stability
in cells often leads to tumourigenesis [4]. The forkhead
protein FOXO3a has been shown to play a role in both
DNA repair pathways and cell cycle checkpoint in
response to DNA damage [5]. Moreover, it has recently
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been reported that FOXO3a can be modulated by onco-
genes such as MUC1 causing increased DNA repair and
enhanced cell survival in response to oxidative stress [6]
and recently FOXM1 was shown in a cancer cell line to
stimulate DNA repair genes following genotoxic stress
[7].
Basal cell carcinoma (BCC) accounts for up to 20% of
all Caucasian carcinomas. We were the first to establish a
link between FOXM1 and tumourigenesis when we dem-
onstrated that FOXM1 is upregulated in BCC [8]. Since
then, FOXM1 has been implicated in the majority of solid
human cancers [reviewed in [9]]. We recently showed
that FOXM1 expression precedes malignancy in a num-
ber of solid human cancer types including oral, oesopha-
gus, lung, breast, kidney, bladder and uterus indicating its
pivotal role in cancer initiation [10]. The present study
investigated the putative early mechanism of UVB and
FOXM1 in skin cancer initiation. We have used a high
efficiency long-term retroviral transduction system to
express exogenous FOXM1B in both immortal and pri-
mary normal human epidermal keratinocytes (NHEK) to
replicate oncogenic levels found in cancer cells. Using
Affymetrix SNP microarray to profile genomic instability
we show that upregulation of FOXM1B in epidermal
keratinocytes results in genomic instability and that this
is augmented by UVB, a major aetiological factor in BCC.
Methods
Cell culture
Primary NHEK and N/TERT cells [11] were cultured in a
low calcium (0.06 mM) EpiLife® keratinocyte growth
medium (#M-EPI-500-CA; Cascade Biologics, TCS Cell-
Works Ltd., Buckinghamshire, UK.) with growth supple-
ments (HKGS, #ZHS-8943; Cascade Biologics). Cells
were grown at 37°C in a humidified atmosphere of either
5% (for EpiLife) or 10% (for DMEM) CO2/95% air.
Real-time quantitative PCR
Poly-A+ mRNA extraction, reverse transcription and real-
time absolute quantitative PCR (qPCR) protocols are
MIQE compliant [12] and were performed as described
previously [10] using a LightCycler LC480 instrument
(Roche Diagnostic). EGFP primers GFP-F2, 5'-TGGC-
CGACAAGCAGAAGAAC-3' and GFP-R2, 5'-
CTTCTCGTTGGGGTCTTTGCTC-3' were used to
quantify the levels of viral transduction by measuring the
EGFP transgene (will detect both EGFP and EGFP-
FOXM1B transgenes) copy number present in the
genomic DNA of transduced cells. Viral supernatant were
titrated to achieve FOXM1B mRNA expression levels of
around 5 to 10-fold upregulation over normal NHEK.
This level of FOXM1B upregulation was found in various
keratinocyte cancer cell lines such as UK1 and SCC15
[10]. Statistical analysis was performed using the Graph-
Pad InStat software (V2.04a, GraphPad Software, San
Diego, CA) for Student's t-test analysis.
Retroviral transduction and FOXM1 reporter assay
Retroviral supernatant and transduction procedures were
performed as reported previously [8,10,13]. Equal levels
of EGFP and EGFP-FOXM1B expression were achieved
by serial retroviral supernatant titration experiment and
subsequently EGFP copy number confirmed by qPCR
using genomic DNA extracted from transduced cells.
UVB irradiation, FACS analysis and cell viability assay
Semi-confluent cells in 10 cm2 dishes were rinsed and
covered with a thin layer of PBS (2 ml) for UVB irradia-
tion (UVP CL-1000 Ultraviolet Cross-Linker with F8T5
bulbs) with lids removed during irradiation. UVB-dose
titration experiment was performed to determine an
intermediate dose that produces partial apoptosis at 24
hours for primary NHEK, N/TERT and HaCaT were
found to be 10-20 mJ/cm2. For FACS-propidium iodide
analysis, culture medium was centrifuged together with
trypsinised cells to collect all cells including detached
cells. Each cell pellet was resuspended in 100 μl PBS and 1
ml 70% ethanol was then added and FACS performed.
Western blotting
Protein samples were separated on SDS-polyacrylamide
gels and transferred to nitrocellulose membrane (Hybon-
C Extra, Amersham Pharmacia) according to standard
protocols. Antibodies used were rabbit polyclonal anti-
FOXM1 (K-19, Santa Cruz), mouse monoclonal anti-p21
(Santa Cruz), rabbit polyclonal anti-phospho-p53 (Ser
15) (Cell Signaling), rabbit polyclonal anti-GFP (Abcam),
rabbit polyclonal anti-phospho-p38 MAPK (Cell Signal-
ing), rabbit polyclonal anti-PARP (Cell Signaling) and
mouse monoclonal anti-GAPDH (Abcam).
Time-lapse Fluorescence microscopy and digital pixel 
densitometry
To synchronize cells at G1/S phase by double thymidine
block, 2 × 105 cells were plated in 6 cm dishes. When cells
reached 40-50% confluence, 2 mM thymidine was added
and incubated for 16 hours in EpiLife medium without
growth supplements. Cells were then washed twice with
PBS and grown in complete medium for another 9 hours.
Thereafter, cells were treated again with 2 mM thymidine
in growth supplement-free EpiLife medium for another
12-16 hours. Release from the second thymidine block
was performed by washing twice with PBS and replacing
with complete EpiLife growth medium when cells were
exposed to UVB (0 hour). Time-lapse microscopy was
performed at 20 minute intervals for 72 hours where n =
6 fluorescence and brightfield images were recorded from
each test well at each time point using the Metamorph
software linked to a fluorescence microscope (Nikon
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Eclipse TE200S) equipped with a temperature-controlled
humidified chamber with 5% CO2/95% atmospheric air.
Digital pixel densitometry was performed as described
previously [10].
SNP Microarray Mapping Assay
Genomic DNA (gDNA) samples were processed for SNP
Mapping 10K (V2.0) XbaI Assay protocol (Affymetrix
Inc., Santa Clara, CA) array analysis as described previ-
ously [10,14]. LOH and LOH likelihood were analyzed
using Affymetrix Copy Number Analysis Tool software
(CNAT, version 4) [15] and CNV obtained using Copy
Number Analyzer for GeneChip (CNAG, version 2) [16].
The mean ± SEM of SNP call rates for all samples (n = 21
chips) used in this study was 96.77% ± 0.00484. Grouping
criteria of 10 adjacent SNPs were used to identify CNV
and LOH loci and putative genes within or adjacent these
loci were identified using IdeogramBrowser (version
0.20.0) [17] based on NCBI Human Genome Assembly
(Built 36.2 database). Raw SNP genotype data files have
been deposited at the NCBI's Gene Expression Omnibus
database [GEO:GSE16937].
Results
UVB dose-dependently elevates FOXM1 protein stability 
and accumulation in keratinocytes
We have recently shown that upregulation of FOXM1B in
oral keratinocytes induced genomic instability and that
this was augmented by nicotine [10]. Because FOXM1B is
upregulated in BCC [8] and since ultraviolet B (UVB,
290-320 nm) is known to be one of the etiological factors
in BCC formation [18] we investigated the effects of
FOXM1B expression on human keratinocytes and their
response to UVB.
We have used retrovirus-mediated transduction of
EGFP-FOXM1B fusion protein under the control of a
constitutive CMV promoter, in both primary normal
human epidermal keratinocytes (NHEK) and the hTERT-
immortalised keratinocyte cell line N/TERT which
retains normal epidermal keratinocyte differentiation in
organotypical cultures and has functional p53/p21 [11].
The system of FOXM1 over-expression used herein has
been previously used and confirmed to produce tran-
scriptionally active FOXM1 protein [8,10]. Furthermore,
we have previously shown that primary human skin kera-
tinocytes retain active FOXM1 protein which binds to
and activates the promoter of CEP55 gene [10]. Fluores-
cence activated cell sorting (PI-FACS) with propidium
iodide of non-irradiated keratinocytes showed no obvi-
ous change in cell cycle of FOXM1B overexpressing kera-
tinocytes (see below) and is consistent with the lack of
cellular phenotype previously reported [19,20].
However, upon UVB irradiation, we found that UVB
dose-dependently increased the expression of EGFP-
FOXM1B in both transduced primary NHEK (>6.3-fold
increased over non-irradiated cells) and N/TERT (>160-
fold; Fig. 1A-B). The dramatic induction of EGFP-
FOXM1B in N/TERT compared to primary NHEK may
be due to the lower baseline EGFP-FOXM1B expression
levels in N/TERT cells compared to primary NHEK prior
to UVB exposure (see below) and which may reflect
higher turn-over of EGFP-FOXM1B protein in N/TERT.
The consistently higher levels of EGFP-FOXM1B in pri-
mary NHEK prior to UVB was not due to unequal trans-
duction efficiency because following UVB, both cell types
showed over 95% EGFP-FOXM1B re-expression. qPCR
analyses showed that gDNA extracted from EGFP and
EGFP-FOXM1B transduced cells contain similar levels of
EGFP viral transgene indicating that equal viral transduc-
tion efficiency was achieved (data not shown). Moreover,
UVB did not affect the EGFP protein level in either cell
types indicating that the UVB-induced expression of
EGFP-FOXM1B was not due to non-specific activation of
the CMV promoter.
To understand how UVB increases FOXM1 protein lev-
els, we used time-lapse fluorescence microscopy to visua-
lise the dynamics of EGFP-FOXM1B protein expression
in live N/TERT cells from 0-72 hours following UVB irra-
diation. All N/TERT cells were synchronised at G1/S
phase by double thymidine block prior to the experiment.
Cell cycle phases were confirmed by PI-FACS analysis.
Non-irradiated EGFP-FOXM1B expressing cells showed
increased fluorescence beginning at 8-10 hours and
which reached maximum expression levels (~3-fold, Fig.
1C) at 15-25 hours, consistent with the role of FOXM1B
in S and G2/M phase expression. In contrast, UVB-irradi-
ated EGFP-FOXM1B expressing cells showed a very rapid
increase in fluorescence beginning at 3 hours (~2.5-fold,
p < 0.01; Fig. 1C) increasing to over ~8-fold at 24 hours
and still remaining high at 48 hours (~9-fold, p < 0.001;
Fig. 1C). This pattern of fluorescence expression was con-
sistent with EGFP-FOXM1B protein levels detected by
immunoblotting following UVB (Fig. 2A). Using qPCR,
mRNA harvested at 0, 3 and 6 hours post UVB showed
that FOXM1B mRNA expression was significantly sup-
pressed, whereas, control non-irradiated cells showed
rapid increase in FOXM1B expression upon release from
growth arrest (Fig. 1D). To confirm that the fluorescence
levels correlated with EGFP-FOXM1B protein, we per-
formed immunoblotting using a GFP antibody to deter-
mine the level of EGFP and EGFP-FOXM1B protein in
cells before and after UVB exposure. In agreement with
fluorescence levels, UVB dramatically increased EGFP-
FOXM1B protein level 24 and 48 hours after UVB irradi-
ation but had no effect on EGFP alone (Fig. 1E).
In non-irradiated cells, EGFP-FOXM1B protein levels
were very low suggesting a rapid turn-over of FOXM1B in
cycling cells [21]. EGFP expressing cells did not show
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Figure 1 UVB dose-dependently stabilised FOXM1B protein expression through inhibition of proteolysis. (A) Fluorescence and phase-con-
trast microscopy of EGFP or EGFP-FOXM1B transduced cells 24 hours following UVB exposure. (B) Digital densitometry of fluorescence micrographs 
in (A) as mean ± s.e.m. (n = 3) fold fluorescence activation over control un-irradiated cells. Statistical significance levels: *(P < 0.05), **(P < 0.01) and 
***(P < 0.001). (C) Time-lapse fluorescence microscopy of EGFP-FOXM1-transduced N/TERT cells following no-exposure (controls) or UVB irradiation. 
Each point represents mean ± s.e.m. (n = 6) fold fluorescence activation over control un-irradiated cells at time 0 hour. (D) qPCR showing no change 
in FOXM1B mRNA during the first 6 hours following UVB exposure. Control non-irradiated cells showed significant increase in FOXM1B mRNA, corre-
sponding cell cycle phases were verified by FACS analyses. (E) Immunoblots showing increased in EGFP-FOXM1 protein levels (using GFP antibody) 
at 24 and 48 hours following UVB exposure. EGFP-expressing N/TERT showed no change in EGFP protein levels at all time points. GAPDH showed 
sample loading density in each blot. (F) Proteasomal proteolysis inhibition by MG132 prevented protein degradation leading to stabilisation of 
FOXM1B proteins. N/TERT cells transduced with EGFP-FOXM1B were treated with either vehicle (0.001% DMSO) or MG132 (1 μM; 24 hours). Fluores-
cence densitometry showed over 95% ***(P < 0.001) re-activation of EGFP-FOXM1B following MG132 treatment. (G) Immunoblots showing FOXM1 
protein stabilisation by UVB and MG132.
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Figure 2 Upregulation of FOXM1B sensitises cells to UVB-induced apoptosis. (A) FOXM1B upregulation preferentially activated p21, p38, p53 
and increase PARP cleavage in primary NHEK following UVB exposure compared to EGFP controls. Immunoblots of EGFP-FOXM1B (using GFP anti-
body; EGFP-FOXM1B at ~130 kD and not shown are the EGFP bands which run at ~27kD), phospho-p38 MAPK, phospho-p53 (Ser 15), p21, PARP and 
GAPDH on primary NHEK transduced with either EGFP (GFP) or EGFP-FOXM1B (FOX). Protein lystates were harvested from cells at time 0 (control un-
irradiated), 3, 6 and 24 hours following UVB irradiation as indicated. (B) Digital densitometry graphical representations of data in (A). (C) UVB irradiated 
FOXM1B-overexpressed cells showed a significant *(P < 0.05) 2.4-fold (5.8% in EGFP cells vs 14% in FOXM1B cells) increased in Sub-G1 population. This 
result is a representative of 3 independent experiments performed in different occasions using different primary NHEK cells.
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fluctuations in protein level before or after UVB exposure
(Fig. 1E). Because a significant activation of EGFP-
FOXM1B fluorescence was seen as early as 3 hours fol-
lowing UVB irradiation and yet FOXM1B mRNA expres-
sion was not activated at this time point (Fig. 1D)
suggests that the increase in EGFP-FOXM1B fluores-
cence was not due to non-specific UVB-induced activa-
tion of the CMV promoter. To investigate whether UVB-
induced increase in EGFP-FOXM1B fluorescence was
due to protein stabilisation, we treated EGFP-FOXM1B
expressing N/TERT cells with either vehicle (0.001%
DMSO) or a proteasomal proteolysis inhibitor MG132
[22]. We showed that MG132 (1 μM, 24 hours), but not
vehicle (0.001% DMSO, 24 hours), significantly increased
EGFP-FOXM1B fluorescence level by more than ~240-
fold in previously non-irradiated N/TERT cells (Fig. 1F).
MG132 did not affect EGFP fluorescence level. The high
level of EGFP-FOXM1B fluorescence seen after MG132
treatment indicates that majority of the transduced cells
carry the EGFP-FOXM1B transgene (i.e. viral transduc-
tion was highly efficient) and that the rapid EGFP-
FOXM1B protein turnover could be stabilised by inhibi-
tion of proteolysis. Furthermore, inhibition of de novo
protein synthesis by cycloheximide treatment (25 μg/ml,
24 hours) did not prevent the accumulation of EGFP-
FOXM1B protein following UVB exposure. This is con-
sistent with the qPCR experiments showing that
FOXM1B mRNA levels did not increase following UVB
exposure (Fig. 1D).
To confirm that endogenous FOXM1 protein was also
stabilised by UVB and MG132, a FOXM1-specific anti-
body was used on immunoblots to detect endogenous
FOXM1 protein in N/TERT cells with and without UVB
or MG132 treatments. In agreement with the above data,
endogenous FOXM1 protein was indeed stabilised by
UVB or MG132 treatment (Fig. 1G). However, the level of
endogenous FOXM1 detected in N/TERT keratinocytes
following UVB irradiation was much lower than that of
exogenous FOXM1 suggesting that UVB induced stabili-
sation of FOXM1 alone is sufficient to explain the
increased expression of FOXM1 seen in BCC. In both
cases, untreated samples showed very little detectable
endogenous FOXM1 protein, consistent with a rapid pro-
tein phosphorylation/de-phosphorylation turnover
mechanism in cycling cells [23].
FOXM1B potentiated pro-apoptotic factors in primary 
NHEK
To understand the possible role of FOXM1 in UVB-
induced carcinogenesis, we investigated the levels of vari-
ous pro-apoptotic/stress-response factors such as p21,
p38, p53 and poly(ADP-ribose) polymerase (PARP) in
primary NHEK. Protein levels of p21, phospho-p38
MAPK, phospho-p53 (Ser 15) and cleaved PARP were
found to be preferentially upregulated in FOXM1B-trans-
duced primary NHEK (Fig. 2A, B) compared to EGFP
controls suggesting the existence of oncogenic/replicative
stress induced by constitutive FOXM1B expression.
NHEK cells expressing FOXM1B showed increased p21
protein level compared to EGFP-expressing cells suggest-
ing the existence of oncogenic/replicative stress induced
by constitutive FOXM1B expression. In EGFP expressing
cells, p21 proteins were barely detectable at 3 and 6 hours
following UVB irradiation, whereas, p21 proteins
remained detectable in FOXM1B-expressing cells.
Upregulation of p21 is linked to keratinocyte cell cycle
arrest prior to the onset of terminal differentiation. p21 is
subject to degradation following low doses of UV irradia-
tion, which is a proposed mechanism that allows efficient
DNA repair [24-27]. The fact p21 protein levels are not
suppressed by maximum induction of FOXM1 24 hours
following UVB, suggests that other mechanisms are also
regulating p21 stability in primary human keratinocytes.
Consistent with our finding, a clear reduction of p21 pro-
tein during the first 6 hours after UVB has also been
observed in primary human normal and neoplastic kera-
tinocytes [28].
Another pro-apoptotic protein p38 MAPK also showed
preferential response to FOXM1B expression. FOXM1B-
expressing cells showed increased phosphorylation of
p38 MAPK (Thr 180/Tyr182) protein levels compared to
EGFP-expressing cells. At all time points following UVB
exposure, phospho-p38 MAPK protein level was higher
in FOXM1B-expressing cells compared to control cells.
p38 MAPK activation is known to respond to oncogenic
stress involving the phosphorylation and activation of
p53 following UV radiation [29]. Therefore, the upregula-
tion of p38 MAPK in freshly transduced FOXM1 cells
provides further evidence of an oncogenic stress
response. Similarly, phosphorylation of p53 (Ser 15) fol-
lowing UVB-induced DNA damage is known to enhance
apoptosis [29]. Although FOXM1B did not increase
phospho-p53 protein level in un-irradiated cells, p53 was
preferentially activated by FOXM1B following UVB
exposure especially at 6 and 24 hours post-irradiation
compared to control cells. The marker for apoptosis
PARP also showed preferential response to FOXM1B
expression where PARP cleavage were activated in
FOXM1B but not in EGFP-expressing cells after 3 hours
following UVB irradiation (peaking at 24 hours after
UVB). In agreement, PI-FACS analysis showed that
upregulation of FOXM1B in NHEK did not induce any
cell cycle effects in control cells (without UVB) but
FOXM1B expression enhanced (~2.4-fold) accumulation
of sub-G1 population following UVB compared to EGFP-
expressing cells (Fig. 2C). G1-, S- and G2/M-phase values
for EGFP vs FOXM1B cells after UVB are as follows: G1
(48.3% vs 44.2%), S (23.9% vs 25.1%) and G2/M (21.3% vs
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15.8%), respectively. Collectively, these results show that
in the absence of UVB, FOXM1B upregulation alone
induced low-levels of pro-apoptotic factors without trig-
gering cell cycle arrest or cell death. However, following
UVB exposure, FOXM1B upregulation triggered DNA-
damage checkpoint response genes and sensitised pri-
mary NHEK to cell death.
FOXM1B induces genomic instability in human 
keratinocytes
Given that upregulation of FOXM1B triggered various
DNA damage/pro-apoptotic stress markers (Fig. 2A, B) in
primary NHEK, we hypothesised FOXM1B upregulation
could be inducing genomic instability resulting in the
upregulation of stress markers. We employed the 10K
SNP array to investigate global genomic instability
events. Early passage primary NHEK (passage 1) were
either mock transduced (no transgene expression) or
transduced with either EGFP or EGFP-FOXM1B, left to
grow for 4 days and gDNA was harvested for SNP array
profiling to obtain genomic instability data in the form of
loss of heterozygosity (LOH) and copy number variation
(CNV) (Fig. 3A). EGFP upregulation did not induce any
detectable LOH or CNV in the NHEK. In contrast,
EGFP-FOXM1B upregulation induced a low level but
detectable genomic instability where a small number of
SNPs had undergone LOH (Fig. 3B, blue lines). Interest-
ingly, FOXM1B-expressing cells showed a ~2-fold
increase in LOH likelihood compared to EGFP-express-
ing cells (Fig. 3B, grey lines). Four days of FOXM1B
expression in primary NHEK may not have sufficient
time to accrue definitive LOH/CNV loci. This may
explain the low number of SNPs acquiring LOH in the
FOXM1B expressing cells. We hypothesised that addi-
tional/subsequent genomic insults (for example, UVB or
chemical carcinogens exposure) to FOXM1B overex-
pressing cells may expedite the accumulation of onco-
genic LOH/CNV loci.
Although FOXM1B did not significantly alter genome
ploidy status, CNV (compare red-dot plots in Fig. 3B)
appear to have more fluctuations (instability) in FOXM1B
(genome ploidy ± sd: 1.999 ± 0.208; SNP Call: 97.27%)
compared to EGFP (genome ploidy: 2.000 ± 0.122; SNP
Call: 98.24%) expressing cells. In agreement, when exam-
ining the copy number of individual SNPs, FOXM1B
expressing cells showed ~10-fold increased in CNV (534
losses and 160 gains) compared to EGFP expressing cells
showed almost negligible CNV (65 loss and 0 gain). Simi-
lar results were obtained from two further independent
SNP array experiments with primary NHEK from 2 dif-
ferent normal skin of healthy volunteers (Fig. 3C). The
differing degree of FOXM1B-induced genomic instability
of the three patients is likely due to individual's variations
in intrinsic cellular susceptibility to oncogene expression.
Overall, FOXM1B significantly (6.60-fold, p < 0.05, n = 3;
Fig. 3D) induced genomic instability in primary NHEK.
EGFP upregulation did not induce significant genomic
instability. Because of the high sensitivity of SNP array,
the genomic instability at such early stage (4 days) follow-
ing oncogene expression would otherwise be undetect-
able by other conventional karyotyping methods.
Next, we question whether the acute genomic instabil-
ity induced by FOXM1B was transient or stable. In a sep-
arate experiment, we performed SNP array mapping in
NHEK transduced with either EGFP or FOXM1B at three
consecutive passages (P1, P2 and P3; Fig. 3E). The SNP
data showed that the genomic instability induced by
FOXM1B was maintained and accumulated with increas-
ing passage number. EGFP-expressing cells did not show
accumulation of genomic instability with increasing pas-
sage number. At passage 3, the total number of SNP copy
number instability accumulated in FOXM1B-expressing
cells (112 losses and 272 gains; total: 384 CNV) was sub-
stantially (42.7-fold) higher than in EGFP-expressing cells
(0 losses and 9 gains).
UVB enhances FOXM1B-induced genomic instability
Given the direct induction of genomic instability by
FOXM1B in NHEK, and that FOXM1B induced instabil-
ity in oral mucosal keratinocytes can be augmented by
nicotine [10], we were interested to know whether UVB,
known to be an etiological factor in BCC formation [18],
would also augment genomic instability in primary
NHEK. To test this hypothesis, SNP array were per-
formed on UVB-irradiated NHEK cells expressing either
EGFP or EGFP-FOXM1B. Unfortunately, following UVB
irradiation, primary NHEK (both EGFP and EGFP-
FOXM1B expressing cells) underwent terminal differen-
tiation and cell death which did not allow the clonal
expansion of UVB resistant cells hence precluding further
experiments using primary cells. We therefore performed
these experiments using immortalised N/TERT keratino-
cytes which are more resistant to UVB-induced cell
death. Following UVB exposure >95% underwent cell
death and the ~5% of surviving cells were allowed to pro-
liferate (~50 days in culture) after which gDNA was har-
vested for SNP array analyses.
In agreement with our hypothesis, following UVB
exposure, cells overexpressing FOXM1B, but not EGFP,
showed marked genomic instability especially in chromo-
some 6 and 7 as illustrated in Fig. 3F. EGFP-expressing
cells showed very low levels of random CNV throughout
the genome and no LOH was detected. In contrast,
FOXM1B-expressing cells showed specific genomic
instability in two chromosomes (6 and 7) where a high
number of CNV was observed in groups of >16 continu-
ous SNPs. LOH as a result of copy number loss was
detected at 6q25.1-6q25.3 (SNP location: 149761596 to
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Figure 3 Acute upregulation of FOXM1B induces genomic instability in primary NHEK. (A) Early passage (P1) primary NHEK were either mock 
transduced, EGFP or FOXM1B transduced, left to grow for 4 days and gDNA was harvested for SNP array analysis. LOH and CNV data were obtained 
by comparing test samples (EGFP or FOXM1B) with reference genome (mock transduced NHEK). (B) CNV (Log 2 ratio, red dots), LOH (blue lines) and 
LOH likelihood (grey lines) plots for EGFP or FOXM1B expressing cells. LOH likelihood was calculated based on Affymetrix GTYPE algorithm [15,66]. (C) 
Three normal healthy primary keratinocytes (NHEK#1-3) SNP copy number analysis showing CNV (ploidy number N < 2) and gains (N > 2) in EGFP and 
FOXM1B overexpressing NHEK, respectively. (D) Average fold-increase in genomic instability of the 3 normal primary NHEK cells in C. *(P < 0.05) indi-
cates significant increase in FOXM1B-induced genomic instability (E) FOXM1B-induced CNV (total SNP number undergoing CNV as indicated above 
each bar) showed gradual accumulation during a short-term primary NHEK culture (3 passages, P1, P2 and P3). (F) FOXM1B, but not EGFP, enhances 
LOH and CNV formation in N/TERT cells that survived UVB insult. Ideogram of chromosome 6 and 7 showing regions of CNV and LOH as indicated.
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160783097; ~11Mb; see additional file 1), whereas, copy
number gain was detected in almost whole of chromo-
some 7 (7p21.3-7q36.3).
Discussion
Our previous studies showed that FOXM1B is upregu-
lated in BCC [8] but its role in the tumour initiation
remains unclear. The present study investigated the effect
of upregulating FOXM1B in primary and immortalised
human epidermal keratinocytes. To avoid overexpression
artefacts, we titrated retroviral supernatant to achieve
levels of FOXM1B expression, similar to those found in
various cancer cell lines. This study presents the first evi-
dence that FOXM1B is dose-dependently activated by
UVB through protein stabilisation and its upregulation
alone induces genomic instability in primary human epi-
dermal keratinocytes.
We found that UVB inhibited proteasomal proteolysis
and dose-dependently upregulated FOXM1B protein lev-
els resulting in acute (within 3 hours) FOXM1B protein
stabilisation and accumulation in the absence of de novo
mRNA/protein synthesis. This agrees with a previous
study showing FOXM1 protein stabilisation, rather than
de novo mRNA expression, following UV, ionizing irradi-
ation and Etoposide treatment in a human osteosarcoma
U2OS cancer cell line [7]. However, it is important to
note that whilst UVB was able to upregulate endogenous
FOXM1B and that FOXM1 has been shown to induce its
own expression [30], other factors such as mutations in
PTCH and SMO with subsequent upregulation of Gli
transcription factors are most likely to be responsible for
the initial upregulation of FOXM1 in BCC ([8]). However,
because BCC keratinocytes are very difficult to maintain
in culture, it is not possible to investigate this in primary
tumour cells. However, the direct activating effect of
DNA damage on FOXM1B activity may also explain why
genotoxic agents, such as ionising radiation, chemother-
apy, intensive photochemotherapy and arsenic intoxica-
tion, increase the rate of BCC development [31].
It is known that oncogene expression in normal cells
triggers DNA-damage checkpoint as a first anti-cancer
barrier response to prevent proliferation of damaged cells
[4,32,33]. Our results indicate that acute upregulation of
FOXM1B transiently activated CDK inhibitor p21cip1 and
stress kinase p38 in primary NHEK. In marked contrast
to our study in primary NHEK, Wang et al [34,35] have
shown in murine hepatocytes and human U2OS osteo-
sarcoma cells that FOXM1B expression suppressed
p21cip1 and p27kip1 and promoted cell cycle progression.
One possible explanation for these differences may be the
fact that Wang et al used mouse cells and human carci-
noma cells presumably with diverse or abnormal cellular
background. In support of this, a recent study investigat-
ing the interaction between p53 and FOXM1 showed that
different cancer cell lines exhibit different responses to
DNA damage-induced FOXM1 levels depending on the
p53 expression status [36]. Moreover, we have found that
in the N/TERT immortal keratinocyte cell line with sup-
pressed levels of p16INK4A and compromised checkpoint
mechanism [11], FOXM1B expression downregulated the
levels of p21cip1 (data not shown), suggesting a clear dif-
ference between primary and cancer cell lines in terms of
response to FOXM1B expression. Interestingly, our cur-
rent study shows that upregulation of FOXM1B in pri-
mary NHEK triggered only a minor apoptotic response
despite activation of p21cip1 and p38. This suggests that
upregulation of FOXM1B allowed cells to tolerate signifi-
cantly higher levels of p21cip1 and activation of stress
kinase p38. Upregulation of FOXM1B in primary NHEK
showed enhanced apoptosis following UVB exposure,
which is in agreement with a report showing that DNA
damage in c-Myc-overexpressing normal mammary epi-
thelial cells, sensitizes cells to DNA damage-induced
apoptosis [37]. Despite sensitising cells to UVB-induced
apoptosis, the pro-proliferation survival advantage pro-
vided by the upregulation of FOXM1B may result in a
selection of cells that escape cell death.
The existence of DNA replication stress is a common
feature in human pre-cancerous lesions [38] and recently,
it has been shown that chronic induction of low, but not
high, levels of Ras oncogene activation predisposes cells
to tumour formation without inducing permanent cell
cycle arrest [39]. Furthermore, a recent study showed that
DNA damage upregulates FOXM1 in cells with defective
p53 pathway [36]. This may explain our hypothesis that
upregulation of FOXM1 following UVB exposure occurs
in cells with defective checkpoint mechanism. Therefore,
FOXM1 upregulation may provide a mechanism whereby
cells evade a checkpoint response which allows damaged
cells to proliferate and accumulate genomic instability.
Activation of cellular senescence pathways via the acti-
vation of p21cip1 or p16INK4A causes defects in the DNA
damage response resulting in increased sensitivity to
genotoxic stresses [40]. We propose that FOXM1B-
induced activation of p21cip1 or p38 in NHEK may be a
result of genomic instability and increase sensitivity to
subsequent genotoxic stress (such as UVB) thereby accel-
erating the selection of genetically unstable cells. We
hypothesised that this may be a mechanism whereby
upregulation of FOXM1 by UVB may initiate and expe-
dite carcinogenesis.
Given the role of FOXM1B in maintenance of chromo-
somal segregation and genomic stability [3] and our find-
ings that FOXM1B triggered DNA-damage stress
responses (p21cip1 or p38) in primary NHEK following
UVB exposure, we investigated whether FOXM1B upreg-
ulation may be inducing DNA damage in the form of
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genomic instability. Recent reports have shown that
oncogenes such as Ras induces chromosomal instability
to promote malignant transformation [41]. Moreover, we
have previously shown that genomic instability was wide-
spread in BCC [14]. We have used a well established and
highly sensitive genome-wide Affymetrix SNP mapping
technique to profile and quantify genomic instability in
the form of LOH and CNV. To our knowledge, this study
provides the first evidence that constitutive and acute (4
days) expression of FOXM1B alone in the absent of other
stimuli is sufficient to induce LOH and CNV in primary
normal human keratinocytes. Furthermore, the
FOXM1B-induced genomic instability was accumulated
when these cells were passaged in culture. In support of
this hypothesis, N/TERT cells expressing FOXM1B, but
not EGFP, showed gross chromosomal CNV and LOH
following UVB exposure. Interestingly, numerous genes
(including MAP3K7IP2, SUMO4, p34/ZC3H12D,
LATS1, RAET1 cluster, ULBP cluster, AKAP12, ESR1,
MYCT1, VIP, TIAM2, SOD2, WTAP, MAS1, SLC22A
cluster, IGF2R, etc.; see see additional file 1) found within
the FOXM1B-induced LOH at 6q25.1-6q25.3, have been
previously linked to oncogenesis of various human can-
cers [40,42-53]. Furthermore, in support of our data,
genes including EGFR and IGFB1-3 found within the
UVB/FOXM1B-induced CNV gain in chromosome
7p12-22 were previously reported to be amplified in
HNSCC [54]. This strongly indicates that upregulation of
FOXM1B synergises with oncogenic stress (UVB) to pro-
mote genomic instability which may help cells gain a sur-
vival advantage. In support of our findings in skin
keratinocytes, we recently showed that FOXM1B upregu-
lation directly induces genomic instability in primary
human oral keratinocytes and that nicotine at a genotoxic
concentration promoted FOXM1-induced malignant
transformation in oral keratinocytes [10]. Nevertheless,
further experiments are required to establish whether the
FOXM1B-induced genomic instability is responsible for
generating oncogenic LOH and CNV involved in skin
malignant transformation.
It is known that FOXM1B plays an important role in
the maintenance of genomic stability [3,55] and that
FOXM1B is upregulated in majority of human cancers
[1]. Although FOXM1B at physiological level has been
reported as a regulator of DNA repair [7], its upregula-
tion is likely to interfere with the normal DNA repair
mechanism leading to enhanced genomic instability
rather than enhanced DNA repair. This highlights the
fact that a tight regulation of FOXM1B expression level is
required during the cell cycle for proper maintenance of
genomic stability. Hence, FOXM1B-induced genomic
instability could be a result of aberrant mitotic division
due to aberrant expression of mitotic spindle assembly
genes such as CEPN-F, Aurora B and Plk1 [3,55] and
genes involved in sister chromatids separation and
cytokinesis such as CEP55 which we have recently shown
to be a downstream target of FOXM1B [10]. In support of
our findings, numerous studies have demonstrated that
proteins which are important in DNA repair and the
maintenance of genomic stability, including mitotic spin-
dle-associated proteins are often found amplified in
human cancers, with centrosome amplification being a
well characterized mechanism giving rise to genomic
instability [56]. Furthermore, consistent with our find-
ings, a recent study has shown that upregulation of
FOXM1 cells confer cisplatin resistance in breast cancer
cells through deregulation of the DNA repair pathway
causing genomic instability [57]. CENP-F (mitosin) over-
expression has also been linked to the generation of chro-
mosomal instability in breast cancer patients [58] as well
as in head and neck squamous cell carcinomas [59].
Upregulation of Aurora centrosome kinase has been
associated with genomic instability in primary human
non-small cell lung carcinomas [60], pancreatic cancer
[61], and ovarian cancer derived cell lines [62]. Further-
more, FOXM1B upregulation has been reported in
majority of human cancers [1], suggesting that gain of
FOXM1B function is an important step in human car-
cinogenesis. In agreement, a recent study measured the
levels of aneuploidy, as a marker for genomic instability in
6 different human tumours types, based on genome-wide
gene expression pattern, the study found that FOXM1
was the third highest ranked gene with a consensus
expression pattern significantly associated with genomic
instability in diverse human malignancies [63].
Whilst upregulation of FOXM1B alone can induce
genomic instability, we have found that this mechanism
alone is not sufficient to induce malignant transformation
in NHEK because the rapid replicative exhaustion of
NHEK in culture may not allow sufficient time for cells to
acquire subsequent oncogenic hits necessary for malig-
nant transformation. In support, FOXM1B overexpres-
sion alone did not induce malignant transformation in
oral keratinocytes [10]. Indeed, many studies have shown
that normal human cells are highly resistant to single-
oncogene mediated transformation which usually
requires multiple oncogenic hits [64,65]. In line with our
findings, in the presence of a second oncogenic pressure
such as UVB, FOXM1B, but not EGFP, expressing cells
acquired and accumulated definitive LOH and CNV loci,
suggesting that upregulation of FOXM1B may predispose
cells to malignant transformation. This notion is strongly
supported by our previous finding that FOXM1B-
expressing oral keratinocytes are highly predisposed to
nicotine-induced malignant transformation [10]. Our
current study provided further evidence that upregula-
tion of FOXM1B alone without UVB exposure in primary
NHEK resulted in genomic instability which could be
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retained, accumulated and amplified in multiple cell cul-
ture passages thereby creating an oncogenic selection
pressure prior to UVB exposure.
Conclusions
This study provided several lines of evidence that
FOXM1 protein is accumulated following UVB exposure
in normal human skin keratinocytes. Furthermore, we
have shown that upregulation of FOXM1B induces
genomic instability and potentiated DNA-damage check-
point responses in primary NHEK following UVB geno-
toxic stress. However, the subsequent mechanisms of
genomic instability and checkpoint responses leading to
oncogenesis require further investigation. Nevertheless,
we hypothesise that prolonged and repeated UVB expo-
sure selects for skin cells bearing stable FOXM1 protein
with aberrant checkpoint may allow ectopic cell cycle
entry and subsequent genomic instability. The aberrant
upregulation of FOXM1 serves as a 'first hit' where cells
acquire genomic instability which in turn predisposes
cells to a 'second hit' whereby DNA-damage checkpoint
response (eg. inactivation of p53 or p16 or other TSGs) is
abolished to allow damaged cells to proliferate and accu-
mulate genetic aberrations/mutations required for cancer
initiation.
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Supplemental Table 1: List of genes located within the LOH region of 6q25.1-6q25.3 (refer to Fig. 3F)
Homo sapiens Genome (Build 36.3)
Region: 149,761,596 to 160,783,097
Total genes in region: 113
Start Stop Gene Symbol Orientation Model Evidence Cyto Description
149680756 149774440 MAP3K7IP2 + best RefSeq 6q25.1-q25.3 mitogen-activated protein kinase kinase kinase 7 interacting protein 2
149763188 149763875 SUMO4 + best RefSeq 6q25 SMT3 suppressor of mif two 3 homolog 4 (S. cerevisiae)
149812571 149847723 ZC3H12D - best RefSeq 6q25.1 zinc finger CCCH-type containing 12D
149854088 149855141 LOC729496 - best RefSeq 6q25.1 coiled-coil domain containing 59 pseudogene
149867324 149908864 PPIL4 - best RefSeq 6q24-q25 peptidylprolyl isomerase (cyclophilin)-like 4
149929217 149953760 C6orf72 + best RefSeq 6q25.1 chromosome 6 open reading frame 72
149955762 149957429 LOC645958 + mRNA 6q25.1 hypothetical LOC645958
149957865 150001421 KATNA1 - best RefSeq 6q25.1 katanin p60 (ATPase-containing) subunit A 1
150023744 150081085 LATS1 - best RefSeq 6q24-q25.1 LATS, large tumor suppressor, homolog 1 (Drosophila)
150080520 150081725 LOC645967 + mRNA 6q25.1 hypothetical LOC645967
150087150 150109381 NUP43 - best RefSeq 6q25.1 nucleoporin 43kDa
150112658 150174249 PCMT1 + best RefSeq 6q24-q25 protein-L-isoaspartate (D-aspartate) O-methyltransferase
150181625 150227173 LRP11 - best RefSeq 6q25.1 low density lipoprotein receptor-related protein 11
150242791 150244401 LOC442267 + protein 6q25.1 similar to T-complex protein 1 subunit eta (TCP-1-eta) (CCT-eta) (HIV-1 Nef-interacting protein)
150251294 150253790 RAET1E - best RefSeq 6q25.1 retinoic acid early transcript 1E
150272756 150273418 RAET1F + best RefSeq 6q24.1-q25.1 retinoic acid early transcript 1F pseudogene
150279707 150285907 RAET1G - best RefSeq 6q24.1-q25.1 retinoic acid early transcript 1G
150286358 150289152 LOC100129147 + mRNA 6q25.1 hypothetical protein LOC100129147
150304829 150312064 ULBP2 + best RefSeq 6q25 UL16 binding protein 2
150326836 150336539 ULBP1 + best RefSeq 6q25 UL16 binding protein 1
150340566 150341597 LOC345829 + best RefSeq 6q25.1 basic transcription factor 3, pseudogene 6
150362917 150367986 LOC646024 - protein 6q25.1 similar to UL16 binding protein 1
150382959 150388361 RAET1L - best RefSeq 6q25.1 retinoic acid early transcript 1L
150388781 150396296 LOC100131886 + protein 6q25.1 hypothetical LOC100131886
150405215 150406338 PHBP1 + best RefSeq 6q25 prohibitin pseudogene 1
150427436 150431895 ULBP3 - best RefSeq 6q25 UL16 binding protein 3
150505881 150613221 PPP1R14C + best RefSeq 6q24.3-q25.3 protein phosphatase 1, regulatory (inhibitor) subunit 14C
150689393 150689892 RNU4P1 - best RefSeq 6q25.1 RNA, U4 small nuclear pseudogene 1 (U4/7)
150731721 150767457 IYD + best RefSeq 6q25.1 iodotyrosine deiodinase
150962692 151206492 PLEKHG1 + best RefSeq 6q25.1 pleckstrin homology domain containing, family G (with RhoGef domain) member 1
151190454 151191449 LOC644850 + best RefSeq 6q25.1 phosducin-like 3 pseudogene
151228384 151464716 MTHFD1L + best RefSeq 6q25.1 methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 1-like
151297610 151298849 LOC644860 + mRNA 6q25.1 similar to ADP-ribosylation factor-like protein 4A
151368389 151370114 LOC100131515 + mRNA 6q25.1 similar to MSTP152
151458988 151462762 LOC646104 + best RefSeq 6q25.1 60S ribosomal protein L32 pseudogene
151588352 151588841 LOC442270 - mRNA 6q25.1 similar to 40S ribosomal protein S12
151603202 151719602 AKAP12 + best RefSeq 6q24-q25 A kinase (PRKA) anchor protein (gravin) 12
151726943 151754370 ZBTB2 - best RefSeq 6q25.1 zinc finger and BTB domain containing 2
151767682 151815009 RMND1 - mRNA 6q25.1 required for meiotic nuclear division 1 homolog (S. cerevisiae)
151815115 151832925 C6orf211 + best RefSeq 6q25.1 chromosome 6 open reading frame 211
151856920 151984021 C6orf97 + best RefSeq 6q25.1 chromosome 6 open reading frame 97
152170379 152466099 ESR1 + best RefSeq 6q25.1 estrogen receptor 1
152484515 153000227 SYNE1 - best RefSeq 6q25 spectrin repeat containing, nuclear envelope 1
152529594 152532033 C6orf98 - best RefSeq 6q25.1 chromosome 6 open reading frame 98
152909342 152909942 NANOGP11 + best RefSeq 6q25 Nanog homeobox pseudogene 11
153060723 153087410 MYCT1 + best RefSeq 6q25.2 myc target 1
153113626 153122593 VIP + best RefSeq 6q25 vasoactive intestinal peptide
153260064 153262136 LOC442271 + protein 6q25.2 similar to tubulin, beta, 2
153333351 153345867 FBXO5 - best RefSeq 6q25-q26 F-box protein 5
153345954 153352053 LOC729616 + mRNA 6q25.2 hypothetical protein LOC729616
153351363 153365540 MTRF1L - best RefSeq 6q25-q26 mitochondrial translational release factor 1-like
153373719 153494082 RGS17 - best RefSeq 6q25.3 regulator of G-protein signaling 17
153645061 153645586 LOC389435 - best RefSeq 6q25.2 hCG21078
154301252 154336328 LOC729635 - protein 6q25.2 hypothetical protein LOC729635
154402136 154609693 OPRM1 + best RefSeq 6q24-q25 opioid receptor, mu 1
154517438 154719592 PIP3-E - best RefSeq 6q25.2 phosphoinositide-binding protein PIP3-E
154768125 154873445 CNKSR3 - best RefSeq 6q25.2 CNKSR family member 3
154883034 154888380 LOC100128473 - protein 6q25.2 hypothetical protein LOC100128473
154912343 154913068 LOC100129996 + protein 6q25.2 hypothetical LOC100129996
154939118 154939921 LOC646269 + mRNA 6q25.2 similar to 40S ribosomal protein S4, X isoform
155069475 155070624 LOC646274 + protein 6q25.2 similar to stathmin-like 2
155096204 155196886 RBM16 + best RefSeq 6q25.1-q25.3 RNA binding motif protein 16
155196171 155324305 LOC729436 + mRNA 6q25.2 hypothetical protein LOC729436
155453115 155620549 TIAM2 + best RefSeq 6q25.2 T-cell lymphoma invasion and metastasis 2
155620482 155677318 TFB1M - best RefSeq 6q25.1-q25.3 transcription factor B1, mitochondrial
155626839 155639374 CLDN20 + best RefSeq 6q25 claudin 20
155758194 155818729 NOX3 - best RefSeq 6q25.1-q26 NADPH oxidase 3
157140778 157572094 ARID1B + mRNA 6q25.1 AT rich interactive domain 1B (SWI1-like)
157632661 157665497 C6orf35 - mRNA 6q25.3 chromosome 6 open reading frame 35
157639645 157641264 LOC729517 - mRNA 6q25.3 similar to lactate dehydrogenase A-like 6B
157707005 157717318 LOC641708 - protein 6q25.3 similar to steroid dehydrogenase homolog
157722545 158014965 ZDHHC14 + best RefSeq 6q25.3 zinc finger, DHHC-type containing 14
157990592 157991232 LOC100128551 + mRNA 6q25.3 hypothetical protein LOC100128551
158164282 158286097 SNX9 + best RefSeq 6q25.1-q26 sorting nexin 9
158226134 158283638 LOC100128129 - mRNA 6q25.3 hypothetical protein LOC100128129
158322907 158439556 SYNJ2 + best RefSeq 6q25.3 synaptojanin 2
158450535 158509257 SERAC1 - best RefSeq 6q25.3 serine active site containing 1
158511489 158533375 GTF2H5 + best RefSeq 6q25.3 general transcription factor IIH, polypeptide 5
158578132 158591754 LOC153932 - mRNA 6q25.3 signal recognition particle 72kD pseudogene
158653680 158852848 TULP4 + best RefSeq 6q25-q26 tubby like protein 4
158856599 158857450 LOC727863 - mRNA 6q25.3 similar to Calcyclin-binding protein (CacyBP) (hCacyBP) (Siah-interacting protein) (S100A6-binding p
158877456 158976455 TMEM181 + best RefSeq 6q25.3 transmembrane protein 181
158977497 158985728 DYNLT1 - best RefSeq 6q25.2-q25.3 dynein, light chain, Tctex-type 1
158991034 159105889 SYTL3 + best RefSeq 6q25.3 synaptotagmin-like 3
159066760 159067823 LOC100131449 - protein 6q25.3 hypothetical LOC100131449
159106764 159159247 EZR - best RefSeq 6q25.2-q26 ezrin
159107541 159108521 LOC100129652 + mRNA 6q25.3 hypothetical protein LOC100129652
159139653 159141881 LOC100130544 - mRNA 6q25.3 hypothetical protein LOC100130544
159182137 159198654 LOC202459 - best RefSeq 6q25.3 similar to RIKEN cDNA 2310008M10
159210965 159251373 LOC100130967 + mRNA 6q25.3 similar to hCG2044932
159257828 159263170 LOC442272 - protein 6q25.3 similar to YKT6 v-SNARE protein
159318254 159341186 RSPH3 - best RefSeq 6q25.3 radial spoke head 3 homolog (Chlamydomonas)
159376012 159386172 TAGAP - best RefSeq 6q25.3 T-cell activation GTPase activating protein
159405748 159407256 LOC727911 - mRNA 6q25.3 hypothetical protein LOC727911
159510417 159613130 FNDC1 + best RefSeq 6q25 fibronectin type III domain containing 1
159867010 159867595 LOC642738 - mRNA 6q25.3 similar to 60S ribosomal protein L21
160020138 160034343 SOD2 - best RefSeq 6q25.3 superoxide dismutase 2, mitochondrial
160051887 160055007 LOC100132803 - protein 6q25.3 hypothetical LOC100132803
160068142 160097341 WTAP + best RefSeq 6q25-q27 Wilms tumor 1 associated protein
160068378 160069441 LOC100132279 + mRNA 6q25.3 hypothetical protein LOC100132279
160101280 160103360 LOC100129518 - mRNA 6q25.3 similar to hCG2029803
160102979 160120077 ACAT2 + best RefSeq 6q25.3 acetyl-Coenzyme A acetyltransferase 2 (acetoacetyl Coenzyme A thiolase)
160119520 160130725 TCP1 - best RefSeq 6q25.3-q26 t-complex 1
160121272 160121403 SNORA20 - best RefSeq 6q25.3 small nucleolar RNA, H/ACA box 20
160126616 160126755 SNORA29 - best RefSeq 6q25.3 small nucleolar RNA, H/ACA box 29
160131488 160139451 MRPL18 + best RefSeq 6q25.3 mitochondrial ribosomal protein L18
160141291 160161725 PNLDC1 + best RefSeq 6q25.3 poly(A)-specific ribonuclease (PARN)-like domain containing 1
160247964 160249098 MAS1 + best RefSeq 6q25.3-q26 MAS1 oncogene
160310121 160447573 IGF2R + best RefSeq 6q26 insulin-like growth factor 2 receptor
160434143 160435938 LOC729603 + best RefSeq 6q25.3 calcium binding protein P22 pseudogene
160462853 160499740 SLC22A1 + best RefSeq 6q26 solute carrier family 22 (organic cation transporter), member 1
160557780 160599949 SLC22A2 - best RefSeq 6q26 solute carrier family 22 (organic cation transporter), member 2
160689415 160796004 SLC22A3 + best RefSeq 6q26-q27 solute carrier family 22 (extraneuronal monoamine transporter), member 3
